TPMT testing: Is it essential?

Clinical Dilemmas in Inflammatory Bowel Disease

Volumn , Issue , 2007, Pages 40-44

  Ansari, Azhar ^a   Sanderson, Jeremy D ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Escalation; Metabolism; Monitoring; Myelosuppression; Thiopurine

Indexed keywords

EID: 84889621251     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470750827.ch12     Document Type: Chapter

References (21)

1. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004; 41: 294-302.
2. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
3. Pirmohamed M, James S, Meakin S, Green C, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9.
4. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19-52.
5. McBride KL, Gilchrist GS, Smithson WA, Weinshilboum RM, Szumlanski CL. Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inhibited thiopurine methyltransferase deficiency. J Pediatr Hematol Oncol 2000; 22: 441-5.
6. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-8.
7. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
8. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford) 2004; 43: 156-63.
9. Ansari A, Escudier M, Shobowale-Bakre M, et al. Responses to low dose azathioprine in patients with heterozygous thiopurine methyl transferase deficiency. Gastroenterology 2001; 120 (Suppl.1): A626.
10. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005; 54: 237-41.
11. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
12. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn’s disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005; 100:1121-5.
13. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 1995; 123: 132-42.
14. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000: CD000067.
15. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
16. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathioprine or 6-mercaptopurine: evidence for a potentially serious drug reaction. Gastroenterology 1999; 116: 1506.
17. Marinaki AM, Duley JA, Arenas M, et al. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1393-7.
18. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996; 30: 951-4.
19. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely optimizes thioguanine nucleotide metabolites in inflammatory bowel disease patients not responding to azathioprine. Aliment Pharmacol Ther 2005; 22: 441-6.
20. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
21. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2000: CD000545.